000520.KS KSC
Samil Pharmaceutical Co.,Ltd
1W: +6.2%
1M: +38.7%
3M: +27.4%
YTD: -21.2%
1Y: -13.6%
3Y: +16.4%
5Y: +0.1%
₩8,600.00 ($6.39)
+400.00 (+4.88%)
Weekly Expected Move ±8.2%
₩7186
₩7893
₩8600
₩9307
₩10014
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$6.1B
-334.0% ▼
Capital Expenditures
$7.5B
-32.9% ▼
5Y CAGR: -15.4%
Free Cash Flow
-$13.5B
-347.2% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$1.3B
-69.9% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$5.3B | -$28M | $1.7B | -$5.6B | -$34.7B |
| Depreciation & Amort. | $4.7B | $5.0B | $5.4B | $7.3B | $13.2B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$5.2B | -$9.6B | -$767M | -$8.1B | $7.0B |
| Other Non-Cash Items | $7.2B | $8.8B | $5.5B | $9.0B | $8.4B |
| Operating Cash Flow | $1.4B | $4.2B | $11.7B | $2.6B | -$6.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$33.1B | -$48.7B | -$24.2B | -$5.4B | -$7.7B |
| Acquisitions (Net) | $823M | $273M | $0 | $0 | $5M |
| Investment Purchases | -$10.3B | -$273M | -$585M | $0 | -$300M |
| Investment Sales | $508M | $11.3B | $0 | $0 | $0 |
| Other Investing | -$3.2B | $1.5B | $5.1B | -$990M | $53M |
| Investing Cash Flow | -$45.3B | -$35.9B | -$19.8B | -$6.4B | -$8.0B |
| — Financing Activities — | |||||
| Net Debt Issuance | $37.8B | $34.4B | $16.8B | $16.3B | $16.4B |
| Stock Repurchased | -$2.5B | $0 | -$30M | $0 | $0 |
| Dividends Paid | -$939M | -$1.0B | $0 | $0 | $0 |
| Other Financing | -$2.5B | -$3.7B | -$8.3B | -$8.3B | -$1.1B |
| Financing Cash Flow | $31.9B | $29.7B | $8.5B | $8.0B | $15.3B |
| Net Change in Cash | -$12.0B | -$2.1B | -$997M | $4.2B | $1.3B |
| Cash End of Period | $4.0B | $1.9B | $906M | $5.1B | $6.4B |
| Free Cash Flow | -$31.7B | -$44.5B | -$12.6B | -$3.0B | -$13.5B |